We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Biotech Growth Trust (the) Plc | LSE:BIOG | London | Ordinary Share | GB0000385517 | ORD 25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 1.19% | 937.00 | 937.00 | 945.00 | 941.00 | 927.00 | 937.00 | 32,552 | 16:07:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Unit Inv Tr, Closed-end Mgmt | -32.42M | -41.3M | -1.0034 | -9.34 | 385.66M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 05/2/2010 19:01 | Tipped in this weeks Moneyweek their argument for biotech looks tempting might buy some through III on a monthly basis through portfolio builder | 4wingrove | |
| 26/1/2010 19:28 | Ian - two is a crowd ............... I didn't bother participating in the recent fund raising, as the amount payable (ie the stated NAV) was some way north of the share price. In fact, I meant to write to the board, and ask who on earth would bother (amongst longer term holders) - when this was the case. Whatever, the institutions were keen, and the price has carried on its mild upward trend. Worth tucking away. Mind you, having bought about nine years ago, I'm now only 25% or so down on what I paid. Ho hum.... | damanko | |
| 25/1/2010 10:04 | damanko - sorry to spoil your solitude!! recommendation on CityWire this morning Why Biotech Growth Trust is the pick of the sector | ianbrewster | |
| 17/11/2009 00:11 | I expect no more than a handful of people to look at this. Perhaps IT followers, which will do quite nicely. They will be aware of the difference between Unit & Investment Trusts. Performance wise. Over time. This little IT has gone from star, to basket case - to a decent punt on the biotech industry, over the past decade. | damanko | |
| 16/11/2009 21:08 | Placing & offer for subscription announced today. | damanko | |
| 16/11/2009 19:54 | See graphs above. By the standards of 2008 / 2009, this little Investment Trust has had a reasonably decent year, main investments as under: Celgene United States Amgen United States Gilead Sciences United States Genzyme United States Curis * United States Dendreon United States Biogen Idec United States Vertex US Alexion US Cephalon United States Top 10 Investments $46,237 59.7% | damanko |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
